{"id":"sars-cov-2-rs-antigen-matrix-m-adjuvant","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-20","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4650407","moleculeType":"Unknown"},"_fixedAt":"2026-03-30T17:38:31.963027","_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a recombinant SARS-CoV-2 spike (S) protein antigen produced in insect cells, combined with Matrix-M, a saponin-based adjuvant that enhances innate immune activation and adaptive immune responses. This combination promotes both antibody production and T-cell mediated immunity to protect against SARS-CoV-2 infection and COVID-19 disease.","oneSentence":"This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:44.104Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"},{"name":"COVID-19 prevention in adolescents (age 12+)"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT06409663","phase":"PHASE3","title":"A Strain Change Study for SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2024-10-14","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 Infection","enrollment":60},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05973006","phase":"PHASE3","title":"Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-08-16","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05875701","phase":"PHASE3","title":"Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-03-28","conditions":"COVID-19","enrollment":147},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT06482359","phase":"PHASE2, PHASE3","title":"Lot Consistency Study of COVID-19 and Influenza Combination Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2025-02-01","conditions":"COVID-19, Influenza","enrollment":""},{"nctId":"NCT05925127","phase":"PHASE2, PHASE3","title":"Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-10-16","conditions":"COVID-19","enrollment":994},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT05249816","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine","status":"COMPLETED","sponsor":"Cogna Technology Solutions LLC","startDate":"2022-03-18","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2025 Aug 13","pmid":"40479932","title":"Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).","journal":"Vaccine"},{"date":"2023 Sep 15","pmid":"37210741","title":"Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.","journal":"The Journal of infectious diseases"},{"date":"2022 Nov","pmid":"35963274","title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.","journal":"The Lancet. Infectious diseases"},{"date":"2021 Sep 23","pmid":"34192426","title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.","journal":"The New England journal of medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Updated Novavax COVID-19 vaccine"],"phase":"phase_3","status":"active","brandName":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","genericName":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19. Used for COVID-19 prevention in adults, COVID-19 prevention in adolescents (age 12+).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}